Structure Therapeutics IncNASDAQ:GPCR
- LAST PRICE39.5200
- TODAY'S CHANGE (%)-1.6200 (-3.9378%)
- Bid / Lots39.3600/ 8
- Ask / Lots39.6900/ 8
- Open / Previous Close40.8400 / 41.1400
- Day Range
- 52 Week Range
- Volume314,908
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | GPCR |
|---|---|---|
| 09:32 ET | 3005 | 40.84 |
| 09:33 ET | 4410 | 41.57 |
| 09:35 ET | 1100 | 41.49 |
| 09:37 ET | 2382 | 41.56 |
| 09:39 ET | 2942 | 42 |
| 09:42 ET | 9800 | 41.7175 |
| 09:44 ET | 1896 | 41.34 |
| 09:46 ET | 300 | 41.34 |
| 09:48 ET | 1399 | 41.5801 |
| 09:50 ET | 2620 | 41.45 |
| 09:51 ET | 300 | 41.45 |
| 09:53 ET | 4943 | 41.425 |
| 09:55 ET | 1600 | 41.425 |
| 09:57 ET | 5053 | 41.48 |
| 10:00 ET | 300 | 41.425 |
| 10:02 ET | 2644 | 41.775 |
| 10:04 ET | 100 | 41.75 |
| 10:06 ET | 100 | 41.74 |
| 10:08 ET | 1543 | 41.725 |
| 10:09 ET | 1300 | 41.615 |
| 10:11 ET | 2242 | 41.63 |
| 10:13 ET | 16301 | 41.05 |
| 10:15 ET | 304 | 40.97 |
| 10:18 ET | 1100 | 41.115 |
| 10:20 ET | 695 | 41.11 |
| 10:22 ET | 500 | 40.97 |
| 10:24 ET | 7209 | 41.03 |
| 10:26 ET | 32658 | 40.84 |
| 10:27 ET | 2786 | 40.87 |
| 10:29 ET | 2000 | 40.85 |
| 10:31 ET | 6597 | 40.63 |
| 10:33 ET | 3773 | 40.51 |
| 10:36 ET | 2300 | 40.5 |
| 10:38 ET | 4066 | 40.73 |
| 10:40 ET | 1500 | 40.67 |
| 10:42 ET | 1820 | 40.57 |
| 10:44 ET | 1330 | 40.7 |
| 10:45 ET | 1119 | 40.61 |
| 10:47 ET | 6097 | 41.12 |
| 10:49 ET | 3300 | 41.1 |
| 10:51 ET | 400 | 41.07 |
| 10:54 ET | 6182 | 40.945 |
| 10:56 ET | 3230 | 40.76 |
| 10:58 ET | 870 | 40.63 |
| 11:00 ET | 800 | 40.59 |
| 11:02 ET | 800 | 40.665 |
| 11:03 ET | 600 | 40.6 |
| 11:05 ET | 200 | 40.6 |
| 11:07 ET | 1500 | 40.78 |
| 11:09 ET | 857 | 40.72 |
| 11:14 ET | 1297 | 40.77 |
| 11:16 ET | 5413 | 40.9 |
| 11:18 ET | 15544 | 40.845 |
| 11:20 ET | 7285 | 40.82 |
| 11:21 ET | 3860 | 40.82 |
| 11:23 ET | 500 | 40.88 |
| 11:25 ET | 2578 | 40.865 |
| 11:27 ET | 7041 | 40.62 |
| 11:30 ET | 1888 | 40.655 |
| 11:32 ET | 3727 | 40.655 |
| 11:34 ET | 700 | 40.4 |
| 11:36 ET | 1171 | 40.47 |
| 11:38 ET | 300 | 40.47 |
| 11:39 ET | 400 | 40.41 |
| 11:41 ET | 702 | 40.49 |
| 11:43 ET | 1942 | 40.3 |
| 11:45 ET | 2576 | 40.34 |
| 11:48 ET | 200 | 40.41 |
| 11:50 ET | 100 | 40.385 |
| 11:52 ET | 300 | 40.33 |
| 11:54 ET | 300 | 40.405 |
| 11:56 ET | 300 | 40.43 |
| 11:57 ET | 1600 | 40.52 |
| 11:59 ET | 400 | 40.525 |
| 12:01 ET | 800 | 40.52 |
| 12:03 ET | 500 | 40.55 |
| 12:06 ET | 1600 | 40.44 |
| 12:08 ET | 1959 | 40.22 |
| 12:10 ET | 300 | 40.32 |
| 12:12 ET | 1300 | 40.3 |
| 12:14 ET | 1468 | 40.295 |
| 12:17 ET | 300 | 40.28 |
| 12:19 ET | 5892 | 39.85 |
| 12:21 ET | 1800 | 39.9 |
| 12:24 ET | 1100 | 39.885 |
| 12:26 ET | 300 | 39.88 |
| 12:28 ET | 700 | 39.88 |
| 12:30 ET | 7669 | 39.6 |
| 12:32 ET | 1335 | 39.5295 |
Oct 31, 2024
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek(R) 2024, from 8:30AM ET on Thursday Oct 31, 2024 by Dow Jones
8:30AM ET on Thursday Oct 31, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Structure Therapeutics Inc | 2.4B | -17.7x | --- |
Longboard Pharmaceuticals Inc | 2.3B | -27.5x | --- |
Vera Therapeutics Inc | 2.4B | -20.6x | --- |
CG Oncology Inc | 2.4B | -31.2x | --- |
Keros Therapeutics Inc | 2.2B | -12.0x | --- |
Akero Therapeutics Inc | 2.2B | -9.5x | --- |
Company Information
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578. It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit. It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis.
Contact Information
- Headquarters
- 611 Gateway Blvd Suite 223SOUTH SAN FRANCISCO, CA, United States 94080
- Phone
- ---
- Fax
- ---
Executives
- Independent Chairman of the Board
- Daniel Welch
- Chief Executive Officer, Director
- Raymond Stevens
- Chief Financial Officer
- Jun Yoon
- Chief Technology Officer
- Yingli Ma
- Chief Scientific Officer
- Xichen Lin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.4B |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 57.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.24 |
Book Value | $9.76 |
P/E Ratio | -17.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
